Open AccessJournal Article
Abstract 13035: Impact of Ezetimibe on Hospitalization-Related Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial
Elizabeth A. Magnuson,Khaja Chinnakondepalli,Katherine Vilain,Daniel B. Mark,Glenn Davies,Robert P. Giugliano,Eugene Braunwald,Christopher P. Cannon,David J. Cohen +8 more
Reads0
Chats0
TLDR
The IMPROVE-IT Trial demonstrated that in patients with a Recent Acute Coronary Syndrome, Ezetimibe reduced hospitalization costs in half of the patients treated with the drug.Abstract:
Impact of Ezetimibe on Hospitalization Costs among Patients with a Recent Acute Coronary Syndrome: Results from the IMPROVE-IT Trial Objectives: The IMPROVE-IT Trial demonstrated that in patients w...read more
Citations
More filters
Journal ArticleDOI
Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
TL;DR: The need for coronary revascularisation might be reduced by adding ezetimibe to statin or fenofibrate, and the findings were driven by the largest study, which had weights ranging from 41.5% to 98.4% in the different meta-analyses.
References
More filters
Journal ArticleDOI
Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
TL;DR: The need for coronary revascularisation might be reduced by adding ezetimibe to statin or fenofibrate, and the findings were driven by the largest study, which had weights ranging from 41.5% to 98.4% in the different meta-analyses.